Fidelity European Trust May Factsheet – European equities moved higher

Fidelity

Fidelity European Trust PLC (LON:FEV) monthly factsheet for May 2025.

Portfolio Manager Commentary

European equities ended the month higher, navigating a period of heightened volatility as investors weighed in uncertainty surrounding US trade policies.  

The Trust underperformed the index during the month, primarily due to weak positioning in the consumer staples and consumer discretionary sectors, while gearing had a small positive impact. Shares in 3i Group declined following the release of full-year results to 31 March 2025. Despite a 22% increase, the net asset value (NAV) growth fell short of market expectations. Action, 3i’s largest portfolio company, continued to perform well. Shares in L’Oréal were weak in the absence of any positive catalysts during the month. In contrast, ABN AMRO Bank was a key contributor to performance. The company’s shares advanced following the first quarter of the year 2025 results that were broadly in line with expectations. The holding in Legrand was a top contributor – the stock gained after the company delivered strong first quarter 2025 results, with organic sales surpassing consensus expectations.  

Our focus is on finding attractively valued companies with good prospects for cash generation and dividend growth over the longer term. On a rolling 12-month basis, the Trust recorded NAV and share price returns of 2.8% (net of fees) and 3.5% respectively, compared to the FTSE World Europe ex UK Total Return Index that returned 7.4%.

Fidelity European Trust PLC (LON:FEV) aims to be the cornerstone long-term investment of choice for those seeking European exposure across market cycles.

Share on:
Find more news, interviews, share price & company profile here for:

Are European equities set for a revival?

Marcel Stötzel, Co-Portfolio Manager of Fidelity European Trust, remains positive on Europe’s investment outlook, citing structural reforms, rising defence spending and potential economic integration as key drivers.

Fidelity European Trust continued rise as shares advanced in ASML and AIB

Fidelity European Trust has published its September 2025 factsheet, noting European equities finished the quarter higher despite mixed sector performance.

Investing in Europe: Why investors should remain positive

Co-Portfolio Manager of the Fidelity European Trust PLC (LON:FEV), outlines why he believes quality businesses backed by strong balance sheets and dividend growth potential remain well placed to deliver strong relative returns over the long-term.

Fidelity European Trust rises in August, reporting 16.4% returns in 2025

Fidelity European Trust highlighted strong contributions in August 2025 from KBC Groupe, which upgraded full year guidance, and Novo Nordisk, which advanced on positive trial results and regulatory approval for Wegovy.

Fidelity European Trust Factsheet – July volatility, Legrand and Bankinter gains

Continental European equities were volatile in July, with the Trust underperforming the index due to weak stock selection in financials and healthcare. Novo Nordisk and ASML detracted, while Legrand and Bankinter contributed positively. Over 12 months, the Trust’s NAV rose 1.8% and the share price 1.7%, compared with an 11.3% gain for the index.

European Investment Opportunities – Fidelity’s Quality Focus (LON:FEV)

FEV portfolio manager Marcel Stotzel highlights how quality companies with strong defensive characteristics can help investors navigate uncertainty and achieve long-term growth.

Search

Search